The uptake of new knee replacement implants in the UK:Analysis of the National Joint Registry for England and Wales by Penfold, Chris et al.
                          Penfold, C., Blom, A. W., Wilkinson, J. M., Judge, A., & Whitehouse,
M. R. (2020). The uptake of new knee replacement implants in the
UK: Analysis of the National Joint Registry for England and Wales.





Link to published version (if available):
10.1016/j.arth.2019.10.045
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S0883540319310228. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





The uptake of new knee replacement implants in the UK: Analysis of the 
National Joint Registry for England and Wales 
 
Chris M Penfold, PhD 1+2* 
Ashley W Blom, PhD 1+2 
J Mark Wilkinson, PhD 3 
Andrew Judge, PhD 1+2 
Michael R Whitehouse, PhD 1+2 
 
Affiliations: 
1. Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, 1st Floor 
Learning & Research Building, Southmead Hospital, Bristol, BS10 5NB, UK 
2. National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals 
Bristol NHS Foundation Trust and University of Bristol. 
3. Department of Oncology and Metabolism and The Mellanby Centre for Bone Research, University 
of Sheffield 
* - denotes corresponding author 
Corresponding author contact details: 
Email: chris.penfold@bristol.ac.uk 
Address: Musculoskeletal Research Unit, University of Bristol, School of Clinical Sciences, Learning and 
Research Building, Southmead Hospital, Bristol, BS10 5NB 
Telephone: 0117 41 47872 
Keywords 




Data sharing statement 
Access to the data analysed in this study required permission from the National Joint Registry for 
England, Wales and Northern Ireland Research Sub-committee. 
http://www.njrcentre.org.uk/njrcentre/Research/Researchrequests/tabid/305/Default.aspx contains 
information on research data access request to the National Joint Registry. 
Acknowledgements 
We thank the patients and staff of all the hospitals who have contributed data to the National Joint 
Registry. We are grateful to the Healthcare Quality Improvement Partnership, the National Joint Registry 
Steering Committee, and staff at the National Joint Registry for facilitating this work. This study was 
funded by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust 
and the University of Bristol. The views expressed in this publication are those of the author(s) and not 
necessarily those of the NHS, the National Institute for Health Research or the Department of Health 
and Social Care. 
Disclaimer 
The views expressed represent those of the authors and do not necessarily reflect those of the National 
Joint Registry Steering Committee or Healthcare Quality Improvement Partnership, who do not vouch 
for how the information is presented. The views expressed in this article are those of the authors and 
not necessarily those of the NHS, the NIHR, or the Department of Health. 
Ethics approval 
Patient consent was obtained for data collection by the National Joint Registry. According to the 
specifications of the NHS Health Research Authority, separate informed consent and ethical approval 
were not required for the present study. 
Contributors 
CP, AB, AJ and MW designed the study. CP, AB, JMW, AJ and MW reviewed the published work. CP 
conducted the statistical analysis. All contributed to writing the report. CP had full access to all the data. 
AB and JMW are the guarantors. 
Funding 
This study was funded by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS 




authors and not necessarily those of the NHS, the National Institute for Health Research or the 







Partial (unicondylar or patellofemoral) or total knee replacements (KR) are mainly performed to treat 
end-stage knee arthritis [1]. It is a highly successful surgical procedure with typical 10-year revision rates 
<5% [2]. However, younger patients are more likely to require revision surgery; the lifetime revision risk 
for men having a KR in their 50s is ~35% compared with 5% in their 70s [3]. Such patients may benefit 
the most from developments in KR that lead to reduced revision rates or improved outcomes, but may 
also face higher risk of complications if new implants perform poorly. 
New KR implant designs are introduced with no evidence that they have lower revision rates than 
established prostheses [4,5], and more than a quarter have higher revision rates than existing designs 
[4]. Although there have been no high-profile failures of knee implant design on the scale of metal-on-
metal total hip replacements, patellofemoral KRs have a 3.6x higher annual revision rate compared with 
TKR [6]. Furthermore, the evidence to support decisions about KR implants is limited [7]. The IDEAL 
collaboration, an influential agenda for surgical research, developed a framework for investigations into 
surgical innovations in which they recommended new medical devices have a phased introduction into 
surgical practice [8]. However, we do not know the rate of uptake of new KR implants, whether this is 
compatible with a phased introduction, how many surgeons are using them, and which patients are 
receiving new KR implants. 
Variation between and within regions for common surgical procedures can be wide [9]. Within knee 
replacement surgery, the large number of different implant brands used in primary KRs (e.g. 103 brands 
for total KRs recorded in the National Joint Registry for England, Wales, Northern Ireland and the Isle of 
Man (NJR) in 2016 [10]) may be an important source of variation. Research to understand variation in 
surgical activity may help to understand and reduce avoidable differences in outcomes for patients. 
Aims 
We aimed to: 
1. Describe the uptake of new implants for KRs in the NJR and how this varies between consultants 
2. Compare consultants who use new compared with established KR implants 





Material and methods 
Data Source 
The NJR was established in 2003 [2]. Data entry for Northern Ireland and the Isle of Man commenced in 
2013 and 2015 respectively and therefore they are excluded from this analysis. 
Study sample 
We included patients who received a primary KR for osteoarthritis (OA) with or without other 
indications between 1st January 2008 and 26th February 2017. We used NJR data from 2003 onwards to 
calculate the date each knee implant brand was first used and the total number of implantations. We 
excluded people who had not given consent for recording of personal details and where the brand of 
their KR implant was uncertain. 
Patient involvement 
This study was designed and undertaken without patient involvement. 
Definition of new and established implant brands 
We identified the implant brand from component labels recorded in the NJR and categorised all implant 
brands with a first recorded use by any surgeon on or after 1st January 2008 as ‘new’. Implant brands 
with a first recorded use before 2008 were categorised as ‘established’. We did not separate posterior 
stabilised and cruciate retaining versions of a brand but did consider brands to be separate based on 
mode of fixation (cemented or uncemented) or whether the brand could be used in more than one type 
of knee replacement (TKR, unicondylar or patellofemoral). 
Consultant uptake of new implant components 
All surgeons with operations recorded in the NJR are assigned an anonymised identifier and their role in 
the operation (“consultant in charge” or “operating”) is recorded. Since consultant surgeons are 
ultimately responsible for the choice of implant we have focussed on the uptake by consultant rather 
than operating surgeon. We summarised each consultant’s activity across each calendar-year in which 
they performed ≥1 KR. We considered seven consultant-level factors which may be associated with their 
use of a new implant brand in a calendar-year:  
1. Total volume of KRs performed in that year 
2. Proportion of those KRs performed on patients <55 years old  




b. Percentage of KRs performed on patients <55 years old 
3. Source of funding for KRs  
a. Any KRs funded privately? ‘100% NHS funded’ or ‘some or all privately funded’ 
b. Percentage funded privately 
4. Proportion of KRs performed on patients with an American Society of Anaesthesiologists (ASA) 
grade III-V (<25% and ≥25%) 
5. Number of KR implant brands used in that calendar-year (continuous) 
6. Number of different types of KR procedures performed (TKR, unicondylar and/or 
patellofemoral: scale 1-3) 
7. Time since the surgeon became a consultant (≤2 years, >2 years) 
Patients receiving new implant components 
We used date of surgery to order patients within implant brands and within consultants. We categorised 
patients according to whether the implant they received was new or established. We considered five 
patient-level factors which may be associated with their receipt of new implants:  
1. Age at the time of KR (<55, 55-80, and 80+ years) 
2. Gender 
3. Body mass index (BMI) 
4. ASA grade 
5. Source of funding for procedure: NHS or private 
We selected these categories for age to reflect patients who were having a primary KR at a relatively 
young or relatively old age, the median age at the time of primary KR was 70 years (25%-75% 63-76 
years).[11] 
Statistical analyses 
We described the use of KR components in primary KRs performed since January 1st 2008, the 
cumulative use of new implants in patients, and the count of consultants who used new implants. 
Consultant-level factors 
We included only those people with complete exposure and outcome data for the consultant-level and 
patient-level analysis models (i.e. complete-case analysis). We assumed that data were missing at 




variables in the NJR dataset which were not already in our regression models and which may have 
carried information about the missing data (particularly BMI). 
Our outcome was whether a consultant used a new implant at least once for a KR in a calendar-year. 
The unit of analysis was consultant calendar-years and exposure variables were those consultant-level 
factors defined previously. We used unadjusted and multivariable adjusted multilevel logistic regression 
models, with calendar-years nested within surgeons. 
Patient-level factors 
Our outcome was whether a patient received a new rather than established implant. The unit of analysis 
was patients and exposure variables were those patient-level factors defined previously. Patient-level 
factors were included in multivariable adjusted multilevel logistic regression models, with patients 
nested within surgeons. 
We calculated the proportion of variance in selection of new implants attributable to differences among 
surgeons assuming that this reflected an underlying latent trait, applying the method described by 
Goldstein et al [12]. 
Sensitivity analyses 
We conducted two sensitivity analyses. To determine whether the lack of variability in patients operated 
on by low volume consultants affected our results, we repeated our consultant-level analysis excluding 
calendar-years for consultants in which they performed <10 KRs. We also considered that the 
demographics of patients receiving total, unicondylar and patellofemoral KRs are different, which may 
affect our patient-level analyses. We therefore repeated these analyses by type of KR procedure.  
All analyses were performed using R v3.5.3 [13], using the ‘lme4’ package [14] to fit the mixed effects 
models, ‘performance’ package [15] to estimate model performance and ‘finalfit’ package [16] to 
produce output tables. 
Results 
Overall use of implant components 
Between 1st January 2008 and 26th February 2017, 722,178 primary KRs were performed for OA in 
England and Wales and recorded in the NJR. The mean age of the patients at the time of their primary 
operation was 68.9 years (sd = 9.5 years), 56.4% were female, their ASA grades were I:11.0%, II:73.6%, 




54.0% obese. KRs were performed by 2,675 consultants using 155 different implants. Consultants used a 
median of four different implants (IQR = 2-7, max=23) and performed a median of 142 KRs over the 
period (IQR = 25-403, max=2,578). 
Use of new implant components 
During this period 65 new implants were first used : 44 TKR, 16 unicondylar, four patellofemoral, one 
multi-compartmental system (TKR + unicondylar + patellofemoral). They were introduced at a 
reasonably constant rate of ~7/year (Figure 1). Twenty-two thousand, one hundred and thirty-four 
primary KRs were performed using new implants (3.1% of all primaries in this period). Twenty-eight 
percent (n=759) of consultants who performed a KR in this period used at least one new implant. The 
median number of new implants used by consultants was one (IQR=1-2, max=8). Consultants used new 
knee implants in a median of seven KRs (IQR=2-26, max=707), these comprised a median of 2.5% 
(IQR=0.7-8.4%) of a consultant’s total KR volume. 
The five most frequently used new implants were used in 14,905 KRs (67.0% of KRs using a new implant, 
Table S1 and Figure 3). The most frequently used new implant was the Attune Knee System (DePuy 
Synthes, Raynham, Massachusetts), which was used in 10,036 KRs. Uptake of this implant was rapid 
compared with other implants (2,000 uses within ~1,200 days). In contrast, nearly half of all new 
implants (n=26) have been used in 10 or fewer KRs. 
Consultant-level and patient-level factors associated with new implants 
Our complete case analysis included 502,015 out of a possible 722,178 (69.5%) KRs and 15,422 
consultant calendar-years. We were missing data for BMI (n=210,143, 29.1%), knee implant (n=16,591, 
2.3%), source of funding (n=1,815, 0.3%), and gender (n=2, 0.0%). 
Characteristics of consultants using new knee implant brands 
Consultant-level factors associated with a higher odds of using a new rather than established implant 
brand in a calendar-year were treating a higher proportion of patients aged <55 years old (OR/10 
percentage points=1.16, 95%CI 1.07-1.25, Table 1), performing more KRs per year (OR/10 
KRs/year=1.07, 95%CI 1.05-1.10), receiving private funding for some or all of their KRs (OR=1.41, 95%CI 
1.16-1.72), and using more different implant brands in a calendar-year.  
The odds of using a new rather than established implant brand increased substantially as the number of 
different implant brands increased (OR/additional implant/year=2.57, 95%CI 2.37-2.79). There was 




three (i.e. at least one total, unicondylar and patellofemoral KR) compared with one type of KR (1 vs 3 
KR types/year: OR=1.51, 95%CI 1.10-2.08). There was weak evidence of a 17% decrease in the odds of 
using a new implant brand by consultants who had a higher compared with lower proportion of patients 
with a high ASA grade (OR=0.83, 95%CI 0.68-1.02). Notably, there was a 63% decrease in the odds of 
using a new implant brand for surgeons who had been a consultant for <2 years, compared with those 
who had been a consultant for longer (OR=0.37, 95%CI 0.28-0.50). 
Characteristics of patients receiving new knee implant brands 
A higher proportion of recipients of new versus established implant brands were aged <55 years old 
(8.7% established vs. 14.3%; Table 2), although the main recipients were aged 55-80 years. There was no 
difference in BMI between recipients of established and new implant brands. A higher proportion of 
recipients of new implant brands had ASA grade I (13.0% new vs. 10.9% established). A higher 
proportion of people with privately funded KRs had new implant brands (19.7% new vs. 10.7% 
established). 
Multivariable adjusted multilevel logistic regression models (Table 2) found that patients <55 years old, 
compared with those 55-80, had 63% higher odds of receiving a new rather than established implant 
brand (OR=1.63, 95%CI 1.54-1.72). Women had 17% higher odds than men of receiving a new implant 
brand (OR=1.17, 95%CI 1.13-1.22). People with higher BMI had lower odds of receiving a new implant 
brand (OR for underweight/normal vs. Class III Obese=0.83, 95%CI 0.76-0.91). Higher ASA grade was 
associated with 47% lower odds of receiving new implants (e.g. OR for ASA grades ‘IV + V’ versus ‘I’ = 
0.53, 95%CI 0.35-0.82). Patients with private versus NHS funding had 42% higher odds of receiving new 
implants (OR=1.42, 95%CI 1.35-1.50). 
The proportion of variance in the selection of new implants which is attributable to differences among 
consultants was high in both the consultant-level (adjusted R2=65%, Table 1) and patient-level (adjusted 
R2=83%, Table 2) models. 
Sensitivity analyses 
Results of our first sensitivity analysis (excluding calendar-years for consultants with <10 KRs) were 
consistent with findings from our primary analyses (Table S2), suggesting that low-volume consultants 
did not bias our results. Our second sensitivity analysis (‘patient-level’ analysis by KR procedure type) 
highlighted the expected differences in the demographics of patients receiving the different KR 




likely to be obese and had a lower ASA grade (Tables S3-S5). Notable differences in factors associated 
with receiving a new implant were: the weaker gender association with receiving a new unicondylar 
implant (OR=1.17, 95%CI 0.95-1.45, Table S4) which was largely due to wide confidence intervals, 




We used data from the NJR to describe the uptake of new (first recorded use after 2008) knee implant 
brands for knee replacement surgery in the UK and how uptake varied between consultant surgeons. 
We also explored potential consultant-level and patient-level factors associated with the use of and 
receipt of new implant brands. We found 65 knee replacement implant brands that were first used in 
the NJR between 2008 and 2017. These new brands were used in only a small proportion (3%) of the KRs 
performed in this period and new brands were tried by around a quarter of KR consultants. The Attune 
Knee System comprised nearly half of all KRs which used a new implant brand.  
The main strength of this study is the use of data from the NJR, the largest joint replacement registry 
with good data capture (capturing >95% primary knee replacements in the period studied [17]). We also 
describe in detail the uptake of new knee implant brands and the factors associated with their use at 
both the consultant and recipient level. This study has several limitations. Implant brands were defined 
as new based on their first recorded use in the NJR being later than 2008. However, this does not 
preclude their earlier introduction into other markets and unrecorded use in England and Wales 
(missing primary KRs ~<5%). We have assumed that new implant brands are different from existing 
brands, but they may instead represent minor modifications or a rebadged/renamed version of an 
existing implant brand. We considered the posterior-stabilised and cruciate-retaining versions of the 
Attune Knee System and other brands to differ only minimally (recorded as separate brands in the NJR) 
and combined them in this study. Since we used observational data our findings may be the result of 
residual confounding. We also had limited consultant-level data beyond the details of their surgical 
practice and were therefore unable to include more consultant-level variables. Since the only 
comparable study to date used data on total hip replacements from the same NJR dataset 
(unpublished), the findings from this current study should be considered exploratory. Hospital-level 
factors and regional variation in suppliers may influence implant selection rather than a consultant’s 




information about the surgeons themselves and we therefore were not able to incorporate any 
characteristics of surgeons in our analyses. Finally, we have not considered the clinical outcomes of new 
compared with established knee implant brands. 
We also found that consultants who treated a higher proportion of younger patients had higher odds of 
using a new implant brand. Patients who were younger or had lower ASA grade had higher odds of 
receiving a new implant brand. These findings are consistent with new implant brands being used in 
patients with a higher lifetime risk of revision [3]. Private sector units tend to treat patients with fewer 
comorbidities than publicly funded units (i.e. NHS units) [21]. Our finding that new implants were more 
likely to be used by consultants who perform privately funded operations further supports our 
conclusion that new implant brands are used more often in patients who are healthier but this may also 
be due to other factors. The lower odds of receiving a new implant brand for people with higher ASA 
grades or who were more obese and that people who funded their operation privately had 42% higher 
odds of receiving a new implant brand also support this conclusion. After KR surgery there is a higher 
level of dissatisfaction with the results of surgery among women compared with men [22,23]. Our 
finding that women had slightly higher odds of receiving a new implant brand might represent an 
attempt by consultants to improve postoperative satisfaction among women. 
We found that consultants who used more different implant brands had higher odds of trying a new 
brand. Frequently changing implant brand may lead to poorer outcomes for patients through three 
routes. Firstly, there may be a hospital-level learning-curve effect after switching to a new implant brand 
in which the earliest patients to receive an implant are at elevated risk of early revision [24]. It is 
unknown whether the learning-curve is weaker or stronger at the consultant-level. Secondly, patients 
treated by consultants who use a wide range of different implant brands may have a higher risk of early 
revision [25]. Thirdly, new implant brands may perform no better [5] or worse than established brands 
[4], although future developments may offer improvements in outcomes or cost-effectiveness. Using a 
wide range of implant brands and frequently switching to new brands may therefore conflict with one of 
the main reasons consultants change implant brand, which is to improve their clinical results [26]. 
However, the impact of this elevated risk to patients undergoing knee replacement surgery in the UK is 
likely to be small since only a quarter of consultants in our study tried a new implant brand and they 
used them in only 3% of their KRs. 
We found that surgeons who had become a consultant in the previous two years were less likely to use 




new consultants might be more likely to use new implant brands while transitioning to their new role in 
the surgical team. Our finding of the converse suggests that the use of new implant brands is driven by 
more established consultants. We are not aware of any prior research on this topic. This finding should 
therefore be treated as exploratory and will need to be replicated in other studies. 
Findings from our study could be developed further in several ways. There have been few previous 
studies which have described the uptake of new knee replacement implant brands. We found 
comparable findings in a study of new implant components for total hip replacements, particularly that 
surgeons who used a wide variety of implant components were much more likely to try a new 
component [27]. Similar studies in knees from other countries would allow us to compare our findings, 
and to consider how different health care systems influence the use of new implants. We described the 
uptake of new knee implant brands, but the relative performance of these brands with more established 
brands remains unexplored. Similarly, there may be a learning-curve associated with switching to a new 
implant, but findings have been limited to hospital-level rather than consultant-level learning-curves. In 
order to understand whether there is an inherent increase in revision risk when switching to a new 
implant it may therefore be valuable to explore the consultant-level learning-curve. 
Conclusions 
A large number of new knee replacement implant brands have been introduced into use in the NJR 
between 2008 and 2017, but they have been used in only a small proportion of primary knee 
replacement operations in this period. Patients who are younger and healthier are more likely to receive 
new implants. Consultant surgeons who already use a large number of different knee implant brands are 






[1] Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, et al. Knee replacement. The Lancet 
2012;379:1331–40. doi:10.1016/S0140-6736(11)60752-6. 
[2] National Joint Registry for England, Wales and Northern Ireland. 14th Annual Report 2017. 2017. 
[3] Bayliss LE, Culliford D, Monk AP, Glyn-Jones S, Prieto-Alhambra D, Judge A, et al. The effect of 
patient age at intervention on risk of implant revision after total replacement of the hip or knee: a 
population-based cohort study. The Lancet 2017;389:1424–30. doi:10.1016/S0140-6736(17)30059-
4. 
[4] Anand R, Graves SE, de Steiger RN, Davidson DC, Ryan P, Miller LN, et al. What Is the Benefit of 
Introducing New Hip and Knee Prostheses? The Journal of Bone and Joint Surgery-American 
Volume 2011;93:51–4. doi:10.2106/JBJS.K.00867. 
[5] Nieuwenhuijse MJ, Nelissen RGHH, Schoones JW, Sedrakyan A. Appraisal of evidence base for 
introduction of new implants in hip and knee replacement: a systematic review of five widely used 
device technologies. BMJ 2014;349:g5133–g5133. doi:10.1136/bmj.g5133. 
[6] Chawla H, van der List JP, Christ AB, Sobrero MR, Zuiderbaan HA, Pearle AD. Annual revision rates 
of partial versus total knee arthroplasty: A comparative meta-analysis. The Knee 2017;24:179–90. 
doi:10.1016/j.knee.2016.11.006. 
[7] Gagliardi AR, Ducey A, Lehoux P, Ross S, Trbovich P, Easty A, et al. Meta-Review of the Quantity 
and Quality of Evidence for Knee Arthroplasty Devices. PLOS ONE 2016;11:e0163032. 
doi:10.1371/journal.pone.0163032. 
[8] McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical 
innovation without evaluation: the IDEAL recommendations. The Lancet 2009;374:1105–12. 
doi:10.1016/S0140-6736(09)61116-8. 
[9] Birkmeyer JD, Reames BN, McCulloch P, Carr AJ, Campbell WB, Wennberg JE. Understanding of 
regional variation in the use of surgery. The Lancet 2013;382:1121–9. doi:10.1016/S0140-
6736(13)61215-5. 
[10] National Joint Registry for England W and NI. Prostheses used in hip, knee, ankle, elbow and 
shoulder replacement procedures 2016. 2017. 
[11] National Joint Registry for England. 15th Annual Report 2018. 2018. 
[12] Goldstein H, Browne W, Rasbash J. Partitioning variation in multilevel models. Understanding 
Statistics n.d.;1:14. 
[13] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R 
Foundation for Statistical Computing; 2018. 
[14] Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of 
Statistical Software 2015;67:1–48. doi:10.18637/jss.v067.i01. 
[15] Lüdecke D, Makowski D, Waggoner P. performance: Assessment of Regression Models. 2019. 
[16] Harrison E, Drake T, Ots R. finalfit: Quickly Create Elegant regression Results Tables and Plots when 
Modelling. R package version 0.9.5. 2019. 
[17] National Joint Registry for England, Wales and Northern Ireland. Annual progress: Data 
completeness and quality n.d. http://www.njrreports.org.uk/Data-Completeness-and-quality 
(accessed June 14, 2019). 
[18] Davies C. An analysis of choice: a case study on hip prostheses. University of East Anglia, 2011. 
[19] Burns LR, Housman M, Booth R, Koenig A. Physician preference items: what factors matter to 





[20] Healy WL, Iorio R. Implant Selection and Cost for Total Joint Arthroplasty: Conflict between 
Surgeons and Hospitals. Clinical Orthopaedics and Related Research® 2007;457:57. 
doi:10.1097/BLO.0b013e31803372e0. 
[21] Mason A, Street A, Verzulli R. Private sector treatment centres are treating less complex patients 
than the NHS. Journal of the Royal Society of Medicine 2010;103:322–31. 
doi:10.1258/jrsm.2010.100044. 
[22] Dunbar MJ, Richardson G, Robertsson O. I can’t get no satisfaction after my total knee 
replacement: rhymes and reasons. The Bone & Joint Journal 2013;95-B:148–52. doi:10.1302/0301-
620X.95B11.32767. 
[23] Nam D, Nunley RM, Barrack RL. Patient dissatisfaction following total knee replacement: a growing 
concern? The Bone & Joint Journal 2014;96-B:96–100. doi:10.1302/0301-620X.96B11.34152. 
[24] Peltola M, Malmivaara A, Paavola M. Introducing a knee endoprosthesis model increases risk of 
early revision surgery. Clinical Orthopaedics and Related Research 2012;470:1711–7. 
doi:10.1007/s11999-011-2171-9. 
[25] Australian Orthopaedic Association. Hip, Knee & Shoulder Arthroplasty: Annual Report 2017. 
Australian Orthopaedic Association; 2017. 
[26] Sharkey PF, Sethuraman V, Hozack WJ, Rothman RH, Stiehl JB. Factors influencing choice of 
implants in total hip arthroplasty and total knee arthroplasty: Perspectives of surgeons and 
patients. Journal of Arthroplasty 1999;14:281–7. doi:10.1016/S0883-5403(99)90052-9. 
[27] Penfold CM, Blom AW, Sayers A, Wilkinson JM, Hunt LP, Judge A, et al. Understanding the uptake 
of new hip replacement implants in the UK: A cohort study using data from the National Joint 







Table 1: Results from univariable and multivariable adjusted multilevel logistic regression models showing the association between consultant-1 
level factors and use of new knee implant brands 2 




(n=1,869)1 OR2 (univariable) OR2 (multilevel) 













Percentage of KRs performed on people <55 
years old (median centered)3,4 

































Percentage of KRs privately funded (median 
centred)6,7 








Proportion of KRs performed on patients with 
ASA grade III-IV 
















Number of different KR procedures performed 
in calendar years 





















Number of different implants used in calendar 
year 





















Random effect variance (adjusted) = 0.652 3 
1 – proportions displayed are based on surgeon-calendar years,  4 
2 - odds ratios, 95% confidence intervals and p-values,  5 
3 – percentages exclude consultant-years with no KRs performed on patients <55 years old,  6 
4 - odds ratios and 95% confidence intervals are per additional 10% cases <55 years old,  7 
5 – odds ratios and 95% confidence intervals are per 10 additional cases,  8 
6 – percentages exclude consultant-years with no privately funded KRs,  9 




Table 2: Results from univariable and multivariable adjusted multilevel logistic regression models of age, gender, categorised BMI, ASA grade and 11 
source of funding on receipt of a new knee implant, with category proportions 12 





(n=16,856) OR1 (univariable) OR1 (multilevel) 



































































(6.4%) (5.8%) (0.77-0.90, p<0.001) (0.76-0.91, p<0.001) 










































Random effect variance (adjusted) = 0.834 13 
1 – odds ratios (95% confidence intervals and p-values) 14 




Figure 1: Introduction of new knee implant brands 2008-2017 16 
 17 
 18 




Figure 2: Proportion of knee replacements between January 2008 and February 2017 using new 20 
implants introduced in different time periods (before 2004, 2004-2006, 2006-2008, 2008 onwards) 21 
 22 
 23 














Supplementary material 32 
Table S1: Uptake of new knee implants first used between January 1st 2008 and 26th February 2017 33 
Knee implant brand Implant type Patients Surgeons Date first used 
Attune TKR 10,036 295 Dec-2011 
Zimmer PFJ Patellofemoral 1,501 183 Aug-2008 
Advance MP Stature TKR 1,242 59 May-2008 
Persona TKR 1,206 36 Feb-2013 
Legion TKR 920 46 Feb-2011 
Journey II BCS Oxinium TKR 884 56 Feb-2013 
Triathlon Uni Unicondylar 785 57 Apr-2009 
Unity Knee TKR 736 20 Apr-2012 
Sphere TKR 655 25 Nov-2011 
Scorpio NRG TKR 581 7 Apr-2013 
EvolutionMP TKR 554 11 May-2013 
Saiph TKR 554 17 Sep-2009 
Journey Uni Oxinium Unicondylar 519 65 May-2010 
FHK TKR 240 6 Nov-2013 
iUni G2 Unicondylar 165 20 Apr-2012 
Smiles Bicondylar TKR 156 54 Sep-2008 
CR Flex TKR 153 12 Feb-2010 
GMK TKR 146 7 Mar-2008 
Physica Knee System TKR 136 7 Nov-2013 
Genus Unicondylar 131 5 Mar-2013 
First TKR 108 6 Feb-2014 
Univation Unicondylar 87 10 May-2014 




Knee implant brand Implant type Patients Surgeons Date first used 
Euros Bicondylar TKR 58 2 May-2011 
iTotal G2 TKR 55 12 Jul-2013 
3D TKR 49 3 Jul-2009 
ACS Uni Unicondylar 48 5 Dec-2012 
Trecking Knee TKR 44 6 May-2013 
Ukneetec Unicondylar 34 1 Dec-2010 
GMK Unicondylar Unicondylar 30 7 Mar-2009 
Asdm TCK TKR 29 1 Jul-2009 
HLS Evolution Unicondylar 26 1 Sep-2009 
iTotal G2 XE TKR 26 6 Feb-2014 
Gemini TKR 23 1 Jul-2008 
EnduRo Hinge TKR 20 12 Oct-2011 
iBalance Unicondylar Unicondylar 19 4 Aug-2012 
Journey II CR Oxinium TKR 19 6 Jul-2016 
Vanguard XP TKR 18 4 Aug-2014 
Restoris Unicondylar 16 2 Jul-2016 
 TKR 1 1 Jan-2017 
 Patellofemoral 1 1 Jan-2017 
Gender PF Patellofemoral 9 3 Apr-2012 
Hemicap Patellofemoral Patellofemoral 8 6 Jul-2013 
Zimmer Segmental System TKR 8 7 Feb-2009 
Aequos G1 TKR 4 1 Dec-2011 
Guardian Hinged/Linked Knee TKR 4 3 Mar-2010 
Euros Unicondylar Unicondylar 3 1 Apr-2012 
U2 Knee System TKR 3 2 Nov-2015 




Knee implant brand Implant type Patients Surgeons Date first used 
Evolution Unicondylar Unicondylar 2 1 Aug-2015 
iBalance PFJ Patellofemoral 2 1 Dec-2016 
OSS TKR 2 2 Jan-2015 
Stanmore Hinge TKR 2 1 Jul-2011 
913 System TKR 1 1 Feb-2008 
Axel II TKR 1 1 Jun-2010 
balanSys TKR 1 1 Aug-2016 
balanSys Revision TKR 1 1 Mar-2016 
Cinetique TKR 1 1 Jul-2008 
Columbus Revision Knee TKR 1 1 Nov-2011 
GMK Linked Knee TKR 1 1 Aug-2015 
LCS Complete Revision TKR 1 1 Oct-2009 
LCS Unicondylar Unicondylar 1 1 Aug-2009 
Mathys Unicondylar Knee Unicondylar 1 1 May-2013 
Mega System C TKR 1 1 Mar-2010 
Mets Hinged/Linked Knee TKR 1 1 Nov-2012 
PB Uni Unicondylar 1 1 Apr-2014 











Table S2 Sensitivity analysis 1: Results from multivariable adjusted multilevel logistic regression models 41 
showing the association between consultant-level factors and use of new knee implant brands, 42 
excluding surgeon calendar-years <10 KRs 43 
Dependent: New implant used in 
calendar year  Established1 New1 OR2 (multilevel) 
Any KRs performed on people <55 years 
old? 













Percentage of KRs performed on people 
<55 years old (median centered)3,4 






Number of KRs performed in calendar 
year5 





















Percentage of KRs privately funded 
(median centred)6,7 






Proportion of KRs performed on patients 
with ASA grade III-IV 











Number of different KR procedures 
performed in calendar years 

















Number of different implants used in 
calendar year 




















1 – proportions displayed are based on surgeon-calendar years,  44 
2 - odds ratios, 95% confidence intervals and p-values, 45 
3 – percentages exclude consultant-years with no KRs performed on patients <55 years old,  46 
4 - odds ratios and 95% confidence intervals are per additional 10% cases <55 years old,  47 
5 – odds ratios and 95% confidence intervals are per 10 additional cases,  48 
6 – percentages exclude consultant-years with no privately funded KRs,  49 
7 - odds ratios and 95% confidence intervals are per additional 10% cases privately funded 50 




Table S3 Sensitivity analysis 2a: Results from univariable and multivariable adjusted multilevel logistic regression models of age, gender, 52 
categorised BMI, ASA grade and source of funding on receipt of a new knee implant, with category proportions: TKR sub-analysis 53 





(n=14,417) OR (univariable) OR (multilevel) 














































(1.01, 1.16, p=0.019) 




















(6.6%) (6.2%) (0.83-0.98, p=0.011) (0.90-1.09, p=0.855) 















































Table S4 Sensitivity analysis 2b: Results from univariable and multivariable adjusted multilevel logistic regression models of age, gender, 56 
categorised BMI, ASA grade and source of funding on receipt of a new knee implant, with category proportions: unicondylar sub-analysis 57 





(n=1,354) OR (univariable) OR (multilevel) 



































































(4.3%) (2.8%) (0.39-0.78, p=0.001) (0.26-0.86, p=0.015) 















































Table S5 Sensitivity analysis 2c: Results from univariable and multivariable adjusted multilevel logistic 
regression models of age, gender, categorised BMI, ASA grade and source of funding on receipt of a new 














































































































































 Private 854  
(22.2%) 
197  
(18.2%) 
0.78  
(0.65-0.92, 
p=0.004) 
1.15 
(0.73-1.82, 
p=0.539) 
 
 
